Unlikely to cause harm — often a labeling or packaging issue.
Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.
| Brand name | PROTONIX |
| Generic name | PANTOPRAZOLE SODIUM |
| Active ingredient(s) | PANTOPRAZOLE SODIUM |
| Distributed by / for | Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc, Philadelphia, PA 19101, Under license from Takeda GmbH, D78467 Konstanz, Germany |
| NDC | 0008-0923-51 |
| Full product label | PROTONIX I.V. (pantoprazole sodium) for Injection, Equivalent to 40 mg pantoprazole per vial, For I.V. infusion only, Rx Only, Distributed by Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc, Philadelphia, PA 19101, Under license from Takeda GmbH, D78467 Konstanz, Germany, MADE IN FRANCE; packaged in A) Pfizer Injectables, 1 vial per carton (NDC 0008-0923-51) in a) bundles of 10 unit cartons (NDC 0008-0923-55) and b) 25 x 40 mg Vials per carton (NDC 0008-0923-60); B) NOVAPLUS, 1 vial per carton (NDC 00008-0941-01) in 25 x 40 mg Vials per carton (NDC 0008-0941-03); and C) PREMIERPro Rx, 1 vial per carton (NDC 0008-4001-01) in a) bundles of 10 unit cartons (NDC 0008-4001-10) and b) 25 x 40 mg Vials per carton (NDC 0008-4001-25). |
| Recalling firm | Pfizer Inc. |
| Distribution | Nationwide |
| Quantity | 582,165 vials |
| Recall initiated | 2016-11-22 |
| Report date | 2017-03-22 |
| Recall completed | 2018-06-22 |
| Recall number | D-0516-2017 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | New York NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗